The United Kingdom and the United States have finalized a key bilateral deal that will ensure no import taxes on British pharmaceutical products being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This commitment ensures that import taxes on these crucial products will stay at nothing for a period of the next three years.
This agreement follows previous statements to hike duties on patented drug imports, with figures floated as high as 100%.
"This arrangement between the United Kingdom bolsters the global environment for innovative medicines and establishes long-overdue equity to U.S.–U.K. drug exports," an announcement noted.
Trade Importance
Medicines are one of the the United Kingdom's biggest goods shipped to the America, which is easily the largest market for leading UK drugmakers.
Statistics show that in the year to the end of September, the UK sold drugs worth billions to the US. This amount accounted for a significant portion of total UK exports in that timeframe.
"This guarantee protects employment, boosts capital expenditure and facilitates the UK to emerge as a worldwide center for medical research," a minister commented.
Detailed NHS Changes
The agreement involves several key pledges from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new treatments to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to double overall NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum drug companies must return to the NHS to prevent overspending will be limited at 15%. Previously, repayments topped 20%.
Broader Context
The deal comes amid a protracted tension between the drug companies and the ministers over drug pricing and NHS adoption.
These tensions were exacerbated by arguments that US patients were charged several times more for the same drugs than people in the other developed nations.
Over the last 18 months, several significant manufacturing plans in the UK have been delayed or scrapped, while major funding commitments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS needed to increase expenditure on treatments, noting that its budget allocation on drugs had decreased as a share of its total funding over the last ten years.
